Australia’s CSL to Buy Swiss Drugmaker Vifor for $11.7 Billion

Australian biopharmaceutical giant CSL Ltd said it would buy Swiss drugmaker Vifor Pharma AG for $11.7 billion, aiming to diversify beyond the blood plasma collection business after taking a hit from COVID-19 curbs. Read More